| Mr Charles Ayomide Adedara, PT | |
|
5818 57th Dr Fl 1, Maspeth, NY 11378-2231 | |
| (347) 659-2361 | |
| Not Available |
| Full Name | Mr Charles Ayomide Adedara |
|---|---|
| Gender | Male |
| Speciality | Physical Therapist |
| Location | 5818 57th Dr Fl 1, Maspeth, New York |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184085235 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 039952 (New York) | Primary |
| Provider Name | Stern At Home Physical Therapy Pc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1720563380 PECOS PAC ID: 6002152147 Enrollment ID: O20190905002382 |
News Archive
Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab will be reported at two upcoming medical meetings.
While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease.
Trius Therapeutics, Inc. announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office (USPTO). The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate (TR-701), currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI).
Do not smoke and do not allow yourself to be exposed to smoke because second-hand smoke and third-hand smoke are just as deadly as first-hand smoke, says a scientist at the University of California, Riverside who, along with colleagues, conducted the first animal study of the effects of third-hand smoke.
Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Charles Ayomide Adedara, PT 5818 57th Dr Fl 1, Maspeth, NY 11378-2231 Ph: (347) 659-2361 | Mr Charles Ayomide Adedara, PT 5818 57th Dr Fl 1, Maspeth, NY 11378-2231 Ph: (347) 659-2361 |
News Archive
Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab will be reported at two upcoming medical meetings.
While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease.
Trius Therapeutics, Inc. announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office (USPTO). The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate (TR-701), currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI).
Do not smoke and do not allow yourself to be exposed to smoke because second-hand smoke and third-hand smoke are just as deadly as first-hand smoke, says a scientist at the University of California, Riverside who, along with colleagues, conducted the first animal study of the effects of third-hand smoke.
Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.
› Verified 5 days ago
Mr. Amorsolo Cenon Laureta Jr., P.T. Physical Therapist Medicare: Medicare Enrolled Practice Location: 6440 58th Rd, Maspeth, NY 11378 Phone: 718-316-7072 | |
Mr. Benjamin Calma Manalac, BSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6918 59th Rd, Maspeth, NY 11378 Phone: 646-623-9511 | |
Mr. John Anthony Casey, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6731 52nd Ave, Maspeth, NY 11378 Phone: 718-344-9187 | |
Mrs. Catherine Quinn Ward, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 5224 65th Pl, #6m, Maspeth, NY 11378 Phone: 718-316-8213 | |
Mr. Fernando Leon Suarez, PHYSICAL THERAPY Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 7215 Grand Ave, Maspeth, NY 11378 Phone: 718-803-2058 Fax: 718-426-9155 | |
Eva Agnes Mikrut, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6024 60th Dr, Apt #3c, Maspeth, NY 11378 Phone: 917-482-4597 |